The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Tue., Dec. 6, 8:52 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #53. Perrigo Company plc Elan Corporation, plc

Acquirer: Perrigo Company plc (NYSE:PRGO)
Acquiree: Elan Corporation, plc
Details: Perrigo Company plc (NYSE, TASE: PRGO) ("Perrigo") and Elan Corporation, plc ("Elan") today announced that Perrigo has completed the acquisition of Elan in a cash and stock transaction valued on the date of the announcement at approximately US$8.6 billion. The transaction will create a global healthcare company with an industry-leading growth profile and the geographic scale and scope to continue building a truly differentiated business.

Perrigo is a provider of over-the-counter health and wellness solutions that can be self-managed. Co.'s segments are as follows: Consumer Self-Care Americas, which is focused primarily on the sale of self-care products in categories including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements; Consumer Self-Care International, which develops, manufactures, markets, and distributes European consumer self-care brands in the upper respiratory, pain and sleep-aids, digestive health, vitamins, minerals and supplements; and Prescription Pharmaceuticals, which develops, manufactures, and markets a portfolio of generic prescription drugs.

PRGO SEC Filing Email Alerts Service


Open the PRGO Page at The Online Investor »

Company Name: 
Perrigo Company plc
Website: 
www.perrigo.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding PRGO: 
64
Total Market Value Held by ETFs: 
$952.14M
Total Market Capitalization: 
$4.33B
% of Market Cap. Held by ETFs: 
22.00%
 

Open the PRGO Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree PRGO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.80 out of 4)
68th percentile
(ranked higher than approx. 68% of all stocks covered)

Analysts' Target Price:
PRGO Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 53 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.